CH647410A5 - Biologisch wirksame peptide enthaltende arzneimittel. - Google Patents
Biologisch wirksame peptide enthaltende arzneimittel. Download PDFInfo
- Publication number
- CH647410A5 CH647410A5 CH1218/82A CH121882A CH647410A5 CH 647410 A5 CH647410 A5 CH 647410A5 CH 1218/82 A CH1218/82 A CH 1218/82A CH 121882 A CH121882 A CH 121882A CH 647410 A5 CH647410 A5 CH 647410A5
- Authority
- CH
- Switzerland
- Prior art keywords
- msh
- peptides
- acth
- formula
- endorphin
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 36
- 102000004196 processed proteins & peptides Human genes 0.000 title description 29
- 229940126601 medicinal product Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 27
- 238000012360 testing method Methods 0.000 description 18
- 101800005049 Beta-endorphin Proteins 0.000 description 14
- 241000700159 Rattus Species 0.000 description 14
- 239000000902 placebo Substances 0.000 description 14
- 229940068196 placebo Drugs 0.000 description 14
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 13
- 230000006399 behavior Effects 0.000 description 12
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 12
- 101800000414 Corticotropin Proteins 0.000 description 11
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 10
- 229960000258 corticotropin Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 108010091893 Cosyntropin Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- ZOEFCCMDUURGSE-SQKVDDBVSA-N cosyntropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 ZOEFCCMDUURGSE-SQKVDDBVSA-N 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 6
- 229960004127 naloxone Drugs 0.000 description 6
- WHNFPRLDDSXQCL-UHFFFAOYSA-N α-melanotropin Chemical compound C=1N=CNC=1CC(C(=O)NC(CC=1C=CC=CC=1)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)NC(CCCCN)C(=O)N1C(CCC1)C(=O)NC(C(C)C)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(NC(=O)C(CO)NC(C)=O)CC1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UHFFFAOYSA-N 0.000 description 6
- -1 y-LPH Chemical compound 0.000 description 5
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 108010042362 beta-Lipotropin Proteins 0.000 description 4
- 230000008033 biological extinction Effects 0.000 description 4
- 230000001143 conditioned effect Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 3
- 102400000742 Lipotropin beta Human genes 0.000 description 3
- 102400000747 Melanocyte-stimulating hormone beta Human genes 0.000 description 3
- 101710129905 Melanotropin beta Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 229960002069 diamorphine Drugs 0.000 description 3
- 230000009191 jumping Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- 239000004081 narcotic agent Substances 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 239000003401 opiate antagonist Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108010040117 ACTH (1-10) Proteins 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 102000008064 Corticotropin Receptors Human genes 0.000 description 1
- 108010074311 Corticotropin Receptors Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 230000000945 opiatelike Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000011421 subcutaneous treatment Methods 0.000 description 1
- 230000015946 suckling behavior Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/695—Corticotropin [ACTH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3023813A DE3023813A1 (de) | 1980-06-25 | 1980-06-25 | Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH647410A5 true CH647410A5 (de) | 1985-01-31 |
Family
ID=6105445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1218/82A CH647410A5 (de) | 1980-06-25 | 1981-06-15 | Biologisch wirksame peptide enthaltende arzneimittel. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4410511A (Sortimente) |
| JP (1) | JPS57500829A (Sortimente) |
| AU (1) | AU542296B2 (Sortimente) |
| BE (1) | BE889384A (Sortimente) |
| CA (1) | CA1147654A (Sortimente) |
| CH (1) | CH647410A5 (Sortimente) |
| DE (1) | DE3023813A1 (Sortimente) |
| FR (1) | FR2485374A1 (Sortimente) |
| GB (1) | GB2086396B (Sortimente) |
| IT (1) | IT1144816B (Sortimente) |
| NL (1) | NL8120190A (Sortimente) |
| SE (1) | SE8200757L (Sortimente) |
| WO (1) | WO1982000031A1 (Sortimente) |
| ZA (1) | ZA814055B (Sortimente) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3345358A1 (de) * | 1983-12-15 | 1985-06-27 | Dieter Prof. Dr. Dr. 5883 Kierspe Aderhold | Therapeutisches mittel zur behandlung von fehlfunktionen des menschlichen diencephalon und/oder der hypophyse, insbesondere der multiplen sklerose |
| EP0146113A3 (de) * | 1983-12-15 | 1987-08-19 | Dieter Aderhold | Wirkstoff und therapeutisches Mittel zur Behandlung von Fehlfunktionen des Diencephalon, von Nervenerkrankungen und Erkrankungen der Haut |
| IT1218472B (it) * | 1985-08-30 | 1990-04-19 | Alfio Bertolini | Composizioni farmaceutiche comprendenti acht (1-24) per il trattamento terapeutico degli stati di shock e dell'insufficienza respiratoria e cardiocircolatoria |
| US4844895A (en) * | 1985-11-01 | 1989-07-04 | New York University | Composition containing a peptide fragment of platelet factor four and method for restoring suppressed immune responses |
| GB2269821B (en) * | 1992-08-08 | 1996-06-05 | Shanghai Inst Biochemistry | Memory enhancing peptides and pharmaceutical compositions containing them |
| US10188704B2 (en) | 2015-05-18 | 2019-01-29 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Enhanced melanoma cancer prevention by novel melanotropins |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL130980C (Sortimente) * | 1960-06-03 | 1900-01-01 | ||
| FR1405270A (fr) * | 1963-05-20 | 1965-07-09 | Ciba Geigy | Procédé de préparation d'un polypeptide, à savoir de la beta-msh |
| CH523227A (de) * | 1966-12-30 | 1972-05-31 | Ciba Geigy Ag | Verfahren zur Herstellung neuer Peptidamide mit ACTH-Wirkung |
-
1980
- 1980-06-25 DE DE3023813A patent/DE3023813A1/de not_active Withdrawn
-
1981
- 1981-06-15 CH CH1218/82A patent/CH647410A5/de not_active IP Right Cessation
- 1981-06-15 AU AU72268/81A patent/AU542296B2/en not_active Expired - Fee Related
- 1981-06-15 GB GB8201463A patent/GB2086396B/en not_active Expired
- 1981-06-15 NL NL8120190A patent/NL8120190A/nl unknown
- 1981-06-15 WO PCT/EP1981/000075 patent/WO1982000031A1/en not_active Ceased
- 1981-06-15 JP JP56501930A patent/JPS57500829A/ja active Pending
- 1981-06-16 ZA ZA814055A patent/ZA814055B/xx unknown
- 1981-06-18 US US06/275,049 patent/US4410511A/en not_active Expired - Fee Related
- 1981-06-22 FR FR8112213A patent/FR2485374A1/fr active Granted
- 1981-06-24 CA CA000380521A patent/CA1147654A/en not_active Expired
- 1981-06-24 IT IT67878/81A patent/IT1144816B/it active
- 1981-06-25 BE BE0/205213A patent/BE889384A/fr not_active IP Right Cessation
-
1982
- 1982-02-10 SE SE8200757A patent/SE8200757L/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA1147654A (en) | 1983-06-07 |
| US4410511A (en) | 1983-10-18 |
| GB2086396A (en) | 1982-05-12 |
| GB2086396B (en) | 1983-10-12 |
| BE889384A (fr) | 1981-12-28 |
| AU7226881A (en) | 1982-01-19 |
| SE8200757L (sv) | 1982-02-10 |
| NL8120190A (Sortimente) | 1982-05-03 |
| FR2485374B1 (Sortimente) | 1984-11-30 |
| FR2485374A1 (fr) | 1981-12-31 |
| DE3023813A1 (de) | 1982-01-21 |
| AU542296B2 (en) | 1985-02-14 |
| IT1144816B (it) | 1986-10-29 |
| ZA814055B (en) | 1982-07-28 |
| IT8167878A0 (it) | 1981-06-24 |
| WO1982000031A1 (en) | 1982-01-07 |
| JPS57500829A (Sortimente) | 1982-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69418181T2 (de) | Cytokine dämpfende substanzen | |
| DE69429768T2 (de) | Diagnose und behandlung von erektilen funktionsstörungen | |
| EP0357978B1 (de) | Pharmazeutische Zubereitung zur Behandlung des Diabetes mellitus | |
| DE69207526T2 (de) | Tramadol N-Oxid, dessen Enantiomere und Zusammensetzungen davon, und deren Verwendung | |
| DD156968A5 (de) | Verfahren zur herstellung von neuen angiotensin-ii antagonisierenden oktapeptidestern | |
| DE2415101A1 (de) | Pharmazeutische zusammensetzungen | |
| DE2705514C3 (de) | Nonapeptide und diese enthaltende Arzneimittel | |
| CH661869A5 (de) | Arzneimittel zur behandlung der ulkuskrankheit. | |
| DE2921216C2 (Sortimente) | ||
| CH676425A5 (Sortimente) | ||
| CH647410A5 (de) | Biologisch wirksame peptide enthaltende arzneimittel. | |
| DE3232034A1 (de) | Pharmazeutisches mittel | |
| CH649562A5 (de) | Derivate des methionin-enzephalins. | |
| DE69328792T2 (de) | Behandlung von migräne | |
| EP0025218A1 (de) | Pharmakologisch aktive Peptide und diese enthaltende Arzneimittel | |
| DE69330638T2 (de) | Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem | |
| DE1518057C3 (de) | Injizierbares adrenocorticotropes Hormonpräparat mit prolongierter ACTH-Aktivität | |
| DE2224130C3 (de) | Tryptophanderivate und sie enthaltende pharmazeutische Zubereitungen | |
| DE2750159A1 (de) | Infusionsloesung zur behandlung von hepatischer encephalopathie und ein verfahren zu deren herstellung | |
| DE3239710C2 (de) | Peptid mit Nerven-regenerierenden Eigenschaften | |
| DE60130802T2 (de) | Agonisten und antagonisten von urotensin-ii | |
| DE2648829A1 (de) | Nonapeptide, verfahren zu deren herstellung und diese enthaltende arzneimittel | |
| EP0028716A2 (de) | Motilitätssteigernde Peptide und deren Verwendung | |
| DE2550992C2 (Sortimente) | ||
| DE1793162C3 (de) | Corticotropes Octadecapeptidamid und Herstellung desselben |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |